Bristol-Myers Squibb Makes First Investment In European VC Fund
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb, like Pfizer and GlaxoSmithKline before it, has entered a strategic collaboration with LSP (Life Sciences Partners), a specialist European healthcare investment firm. "This is the first time BMS is partnering with a European healthcare fund and LSP was chosen after a very rigorous selection process," the VC firm told Scrip.
You may also be interested in...
Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.